Department of Obstetrics and Gynecology and Pediatrics, University of Modena and Reggio Emilia, Modena, Italy.
Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Trends Endocrinol Metab. 2020 Jun;31(6):435-447. doi: 10.1016/j.tem.2020.02.002. Epub 2020 Mar 9.
This review details the physiologic roles of two insulin sensitizers, myo-inositol (MI) and d-chiro-inositol (DCI). In the human ovary, MI is a second messenger of follicle-stimulating hormone (FSH) and DCI is an aromatase inhibitor. These activities allow a treatment for polycystic ovary syndrome (PCOS) to be defined based on the combined administration of MI and DCI, where the best MI:DCI ratio is 40:1. Moreover, MI enhances the effect of metformin and clomiphene on the fertility of PCOS women seeking pregnancy. As impaired intestinal transport may lead to unsuccessful inositol treatment, we also discuss new data on the use of alpha-lactalbumin to boost inositol absorption. Overall, the physiological activities of MI and DCI dictate the dosages and timing of inositol supplementation in the treatment of PCOS.
这篇综述详细介绍了两种胰岛素增敏剂——肌醇（MI）和 D-手性肌醇（DCI）的生理作用。在人类卵巢中，MI 是卵泡刺激素（FSH）的第二信使，DCI 是芳香酶抑制剂。这些活性使得可以基于 MI 和 DCI 的联合给药来定义多囊卵巢综合征（PCOS）的治疗方法，其中最佳的 MI:DCI 比例为 40:1。此外，MI 增强了二甲双胍和氯米酚对寻求怀孕的 PCOS 妇女的生育能力的作用。由于肠道转运受损可能导致肌醇治疗失败，我们还讨论了使用α-乳白蛋白来促进肌醇吸收的新数据。总的来说，MI 和 DCI 的生理活性决定了 PCOS 治疗中肌醇补充的剂量和时间。
